RADX Radiopharm Theranostics Ltd IFRS Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1949257 · Fiscal year ends 06/30
Financial factors as of 2025-06-30 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY1,114.3%
TTM net income YoY20.0%
TTM EPS YoY85.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin1.1%
Operating margin-1,050.6%
Net margin-1,055.3%
FCF margin—
EBITDA margin-979.2%
Returns
ROE-105.2%
ROA-48.4%
ROIC (approx.)-239.1%
Asset turnover0.05x
Leverage & solvency
Liabilities / assets50.4%
Debt / equity0.00x
Current ratio2.67x
Interest coverage-584.59x
Cash quality & payout
Operating cash flow / net income0.96x
Accruals ratio-2.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2025*2025-06-30 | FY2024*2024-06-30 | FY2023*2023-06-30 |
|---|---|---|---|
| Income statement | |||
| Revenue | $3.63M | $299,228 | $292,359 |
| Cost of revenue | $3.59M | — | — |
| Gross profit | $39,276 | $299,228 | $292,359 |
| R&D expense | $27.52M | $23.09M | $22.63M |
| SG&A expense | $14.64M | $13.04M | $12.23M |
| Operating income | -$38.17M | -$47.21M | -$34.49M |
| Interest expense | $65,300 | $642,888 | $86,091 |
| Pretax income | -$38.24M | -$47.85M | -$34.57M |
| Income tax | $103,292 | $96,364 | $38,005 |
| Net income | -$38.34M | -$47.95M | -$34.61M |
| EBITDA | -$35.58M | -$44.08M | -$31.19M |
| EPS (basic) | -1.76 | -12.41 | -11.32 |
| EPS (diluted) | -1.76 | -12.41 | -11.32 |
| Weighted avg. shares (diluted) | 2.08B | 386.46M | 305.83M |
| Balance sheet | |||
| Cash & equivalents | $29.12M | $18.58M | $11.70M |
| Receivables | $10.40M | $987,413 | $4.47M |
| Current assets | $39.85M | $22.85M | — |
| PP&E, netmay include right-of-use assets (IFRS) | $53,466 | $60,797 | — |
| Intangibles | $46.57M | $49.09M | $58.54M |
| Total assets | $86.48M | $72.04M | — |
| Current liabilities | $14.93M | $17.58M | — |
| Total liabilities | $43.61M | $44.68M | — |
| Shareholders' equity | $44.79M | $28.12M | $45.58M |
| Cash flow statement | |||
| Operating cash flow | -$36.65M | -$22.98M | -$23.20M |
| Capital expenditure | — | — | $45,306 |
| Free cash flow | — | — | -$23.25M |
| Investing cash flow | $1.77M | -$320,000 | -$1.53M |
| Financing cash flow | $45.43M | $30.20M | $9.22M |
| Depreciation & amortization | $2.60M | $3.13M | $3.30M |
| Stock-based compensation | $1.90M | $2.64M | $3.04M |
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.